GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease.

To build that understanding, as part one of the Your Cancer Is Our Challenge program, GSK sponsored a survey of more than 800 adults with gynecological cancers—including endometrial, ovarian ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

The drug's manufacturer, GlaxoSmithKline, has sought to play down its side-effects, denying until last year that it could be addictive. Mind - along with dozens of people suffering the drug's side ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.72B ...

A Texas firefighter pulled a trapped toddler from the window of a burning apartment building in a daring early morning rescue Sunday, and it was all caught on video. A firefighter, identified in a ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

The findings offer promising support for progressing ADPO-002NP treatment to first-in-human Phase I clinical trials. Adipo ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...